TUDOBEST-LE (Tenofovir & Lamivudine & Efavirenz)

TUDOBEST-LE (Tenofovir, Lamivudine & Efavirenz) is a combination drug used in the treatment of HIV (Human Immunodeficiency Virus) in adult patients. Each tablet contains three antiretroviral agents: 300 mg tenofovir, 300 mg lamivudine, and 600 mg efavirenz.

Tenofovir belongs to the class of nucleoside reverse transcriptase inhibitors (NRTIs) and is active against human immunodeficiency virus (HIV-1 and HIV-2), as well as against hepatitis B virus. Tenofovir blocks HIV-1 reverse transcriptase and hepatitis B polymerase using a special mechanism , as a result of which the synthesis of the virus DNA chain is interrupted.

Lamivudine also belongs to the class of nucleoside reverse transcriptase inhibitors (NRTIs). This substance is a highly effective selective inhibitor of HIV-1 and HIV-2 replication. It also has activity against zidovudine-resistant strains of HIV. To a small extent, lamivudine also blocks HIV RNA and DNA dependent reverse transcriptase.

Efavirenz is an antiretroviral drug that belongs to the class of selective non-nucleoside HIV-1 reverse transcriptase inhibitors (NNRTIs). This substance is a non-competitive inhibitor of HIV-1 reverse transcriptase, but does not block HIV-2 reverse transcriptase and human DNA polymerase (α, β, γ and δ).